The expansion of myeloid-derived suppressor cells (MDSCs) correlates with tumorigenesis in colorectal cancer (CRC). Here, we found a significant association between CD33 + MDSC number and Yes-associated protein 1 (YAP1) and phosphatase and tensin homologue (PTEN) levels in CRC patients (P < 0Á05). Moreover, the CD33 + MDSCs, YAP1 and PTEN were identified as predictors for the prognosis of CRC patients (P < 0Á05). Notably, CD33 + MDSCs were an independent survival predictor for CRC patients through a Cox model analysis. In vitro data determined that the expression levels of YAP1 and PTEN in CRC-derived cell lines were associated with CRC-derived MDSC induction, and the blockade of YAP1 and PTEN decreased CRCderived MDSC induction. A mechanistic analysis revealed that YAP1 promoted CRC-derived MDSC induction by suppressing PTEN expression to up-regulate COX-2, P-AKT and P-p65 in CRC-derived cells, leading to secretion of the cytokine granulocyte-macrophage colony-stimulating factor. Our findings establish a novel mechanism of pro-tumorigenic MDSC induction mediated by ectopic YAP1 and PTEN expression in CRC.
Introduction
Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide, ranking as the third cause of all cancer-related deaths. 1, 2 The pathogenesis of CRC is complex. The clonal evolution of tumours by sequential mutation causes the genotypic heterogeneity of tumour cells, and many oncogenes and metastasis-related genes have been identified in CRC. 1, 3, 4 Yes-associated protein 1 (YAP1) is a downstream effector in the Hippo-YAP signalling pathway. Recent work has verified that YAP1 is critical for the proliferative response observed during intestinal inflammation as well as in sporadic CRC, and YAP1 signalling is generally activated in CRC and CRCderived cell lines. [5] [6] [7] Meanwhile, the deletion of tumour suppressors, such as phosphatase and tensin homologue (PTEN) or tumour protein p53, is common and has been linked to the aetiology of CRC. 8, 9 However, the complex molecular mechanisms of CRC development and progression are not yet fully understood.
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I M M U N O L O G Y O R I G I N A L A R T I C L E
The tumour microenvironment outside tumour cells is a complex mixture of tumour-associated fibroblasts, infiltrating immune cells and signalling molecules, such as cytokines. 10, 11 Among the infiltrating immune cells, myeloid-derived suppressor cells (MDSCs) represent a phenotypically heterogeneous population of immature myeloid cells that support tumours by promoting immunological anergy and tolerance. 12, 13 In a previous study, we identified that the MDSC population is expanded in the peripheral blood and tumour tissues of CRC patients, where it promotes tumour cell growth and suppresses T-cell proliferation. 14 Recently, some studies have identified that the ectopic expression of YAP1 and PTEN may be associated with tumour-promoting inflammation in some cancers, including CRC. 15, 16 However, the molecular mechanism remains unclear.
In this study, we explored the correlations between the tumour expression of YAP1 and PTEN and the expansion of CD33 + MDSCs as well as their clinical relevance in CRC patients. We further investigated the molecular mechanisms of pro-tumorigenic MDSC induction, which is mediated by ectopic YAP1 and PTEN expression in CRC.
Materials and methods

Patients and cell lines
Paraffin-embedded CRC tissues were collected from 145 newly diagnosed CRC patients who did not accept any preoperative chemoradiotherapy at the time of diagnosis at the Sun Yat-Sen University Cancer Centre, Guangzhou, China, 2005-2006 (see Supplementary material, Table S1 ). Among the 145 CRC patients, 84 (57Á9%) were male, the median age was 56Á4 years (range 20-85 years), 60 (41Á4%) were Duke stage A-B, 100 (69Á0%) were at a well-to-moderate histological stage, 69 (47Á6%) exhibited metastasis, 83 (57Á2%) showed progressive disease, and 80 (55Á2%) had died by the end of the follow-up period. Written informed consent to participate was obtained from each patient. This study was approved by the Research Ethics Committee of the Sun Yat-Sen University Cancer Centre. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (www.researchdata.org.cn) with the approval RDD number RDDB2017000053.
The human LS174T, LOVO, SW620 and SW480 CRC cell lines were maintained in our laboratory and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Guangdong Succhi Shiqi Pharmaceutical, Guangdong, China).
Immunohistochemical staining
Serial sections were cut continuously at a thickness of 4 lm. After deparaffinization, sections were analysed by immunohistochemical analysis using a mouse anti-human CD33 antibody (1 : 50; Abcam, Cambridge, UK), rabbit anti-human YAP1 antibody (1 : 300; Proteintech, Rosemont, IL) and monoclonal rabbit anti-human PTEN antibody (1 : 100; Cell Signaling Technology, Danvers, MA). The slides were observed independently by two pathologists. The samples were scored as 0, 1, 2 or 3 when the following percentages of cells were positive for YAP1 or PTEN: < 5% (0 score); ≥ 5% but < 10% (1 score); ≥ 10% but < 50% (2 score); or ≥ 50% (3 score). CD33 staining was evaluated by counting positively stained cells in 10 separate 4009 fields. Rabbit IgG1 (DAKO, Copenhagen, Denmark), mouse IgG1 (DAKO) and normal goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA) were used as negative controls.
Western blot analysis
Western blot analysis was performed using a rabbit antihuman YAP1 antibody, rabbit anti-human YAP1 antibody, rabbit anti-human P-AKT (eBioscience, San Diego, CA), rabbit anti-human P-p65 (eBioscience), rabbit antihuman cyclo-oxygenase subunit 2 (COX-2) (eBioscience), rabbit anti-human NACHT, LRR and PYD domains-containing protein 3 (NLRP3) (Proteintech) or rabbit antihuman interleukin-1b (IL-1b) (Proteintech) at different concentrations. The protein bands were visualized using an ECL detection kit (PerkinElmer Life Science, Waltham, MA). glyceraldehyde-3-phosphate dehydrogenase (Cell Signaling Technology) was included as a control.
Functional MDSC induction in vitro, flow cytometry and proliferation assay CD33 + cells were enriched using human CD33 MicroBeads (Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the manufacturer's instructions; the cells were separated from the peripheral blood mononuclear cells (PBMCs) of healthy donors. The CD33 + cells were co-cultured with CRC-derived SW480, SW620 or LS174T cells in 24-well plates in a Transwell system (0Á4-lm pore; Corning, New York, NY) at a ratio of 1 : 5 for 48 hr. A total of 1 9 10 6 MDSCs in serumfree medium were loaded into the lower chamber; 5 9 10 6 cancer cells were added to the upper chamber. CD33 + cells maintained in medium alone were used as a control. After 48 hr of incubation, the MDSC population was determined by flow cytometry, as described in our previous study. 17 In brief, the MDSC phenotypes were gated within the HLA-DR À cell population that expressed both the CD33 and CD11b antigens. 
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assays for IL-6, granulocyte-macrophage conlony-stimulating factor (GM-CSF), IL-1b and tumour necrosis factor-a were performed using human IL-6 (R&D Systems, Nasdaq, MN), GM-CSF Instant (R&D Systems) and human IL-1b kits (R&D Systems) according to the manufacturers' protocols. The absorption at 450 nm was detected using a 96-well plate reader (Bio-Rad, Hercules, CA).
Statistical analyses
All data are presented as the mean AE SEM. The significance of the differences between mean values was determined using SPSS 13Á0 software (SPSS, Chicago, IL). Two-group comparisons were tested using Student's t-test, and the relationships among PTEN, YAP1, CD33 and clinical pathological features were tested using Pearson's chi-square test. Optimal cut-offs for YAP1, PTEN and CD33 + cells were assessed by performing a minimum P-value estimation using X-TITLE software (Version 3.6.1, Yale University, New Haven, CT), and relapse after a response, death or the date of the last follow up was used as an endpoint. Using the validation cohort, Kaplan-Meier survival curves were constructed using the log-rank test to evaluate overall survival (OS) and disease-free survival (DFS) at the optimal cut-off point. A Cox multivariate analysis (Cox regression) was performed and included biological markers known to be predictive factors, including Duke stage and histological grade. A value of P < 0Á05 was considered significant.
Results
The tumour expression of YAP1 and PTEN in the tumour microenvironment and the correlation with the abundance of CD33 + MDSCs in CRC patients
Our previous study identified that MDSC populations were expanded in the peripheral blood and tumour tissues of CRC patients and promoted tumour progression. 14 In the current study, to investigate the related molecular mechanisms of CRC-induced MDSC expansion in CRC, we first identified increased CD33 + MDSC numbers and YAP1 expression levels along with decreased PTEN expression levels in tumour tissues compared with those of tumouradjacent tissues from the same CRC patients (Fig. 1a-d , P < 0Á05, n = 40). The density of CD33 + MDSCs was significantly positively correlated with YAP1 expression (P = 0Á005, R = 0Á205, n = 145) but negatively associated with PTEN expression (P = 0Á040, R = À0Á152, n = 145). In addition, the level of YAP1 was prominently negatively associated with that of PTEN (P = 0Á042, R = À0Á149, n = 145) in the CRC microenvironment ( Fig. 1e-g ).
Relationships among YAP1, PTEN and CD33 + MDSC levels and clinical features
The median density of each immunohistochemical variant was used to separate the patients into high-level and lowlevel groups according to the levels of YAP1, PTEN and CD33 + MDSCs. The correlations among the levels of YAP1, PTEN and CD33 + MDSCs and clinical features are listed in Table 1 . The density of CD33 + MDSCs and YAP1 expression were both significantly positively associated with adverse clinical features, including an advanced Duke stage, a poor histological grade and metastasis (P < 0Á05), whereas the level of PTEN was significantly associated with favourable clinical features, including an early Duke stage and a good histological grade. In addition, the level of PTEN was related to the sex of the patients; females had a higher level of PTEN than males (P < 0Á05). The levels of YAP1, PTEN and CD33 + MDSCs and patient survival
The 10-year DFS and OS rates for all 145 patients were 38Á4% and 44Á8%, respectively, in this study (Fig. 2a) . When the survival outcomes of patients were compared according to the levels of CD33 + MDSCs and YAP1 expression, the high-level CD33 + MDSC (63Á0% of total) and YAP1 (38Á0% of total) expression groups showed poorer DFS and OS than did the low-level CD33 + MDSC (DFS: P = 0Á000; OS: P = 0Á000; Fig. 2b ,c) and YAP1 (DFS: P = 0Á000; OS: P = 0Á000; Fig. 2d,e) nificantly higher in tumour tissues than in tumour-adjacent tissues from the same patient, whereas the level of PTEN was significantly lower in tumour tissues than in tumour-adjacent tissues from the same patient (n = 40, P < 0Á05). (e-g) Correlation analysis between YAP1 or PTEN and tumour-infiltrating CD33 + cells. Our observations indicated that YAP1 expression was significantly positively associated with the number of tumour-infiltrating CD33 + cells (e, R = 0Á205, P = 0Á005, n = 145), whereas PTEN expression was significantly negatively associated with the number of tumour-infiltrating CD33 + cells (g, R = À0Á152, P = 0Á040, n = 145) and YAP1 expression (f, R = À0Á149, P = 0Á042, n = 145).
The statistical analysis was performed using Pearson's correlation coefficient and linear regression. R, Spearman's correlation; P, significance of correlation. survival outcomes of patients were compared according to the levels of PTEN expression, the high-level PTEN (50Á7% of total) expression group demonstrated favourable DFS and OS compared with the low-level PTEN expression group (DFS: P = 0Á036; OS: P = 0Á037; Fig. 2f,g ). In the univariate analysis of potential prognostic indicators of DFS and OS, in addition to the density of CD33 [P = 0Á000; hazard ratio (HR) = 7Á95; 95% CI = 3Á343-16Á03 and P = 0Á000; HR = 10Á01; 95% CI = 4Á573-21 Á913], YAP1 (P = 0Á000; HR = 3Á034; 95% CI = 1Á956-4Á705 and P = 0Á000; HR = 3Á067; 95% CI = 1Á961-4Á798) and PTEN (P = 0Á039; HR = 0Á629; 95% CI = 0Á405-0Á978 and P = 0Á040; HR = 0Á625; 95% CI = 0Á399-0Á979), the Duke stage (P = 0Á000; HR = 4Á445; 95% CI = 2Á625-7Á529 and P = 0Á000; HR = 3Á986; 95% CI = 2Á349-6Á764), the histological grade (P = 0Á000; HR = 0Á297; 95% CI = 0Á189-0Á469 and P = 0Á000; HR = 0Á275; 95% CI = 0Á174-0Á435) and the presence of metastasis (P = 0Á000; HR = 16Á730; 95% CI = 9Á082-30Á816 and P = 0Á000; HR = 13Á797; 95% CI = 7Á527-25Á289) were significant prognostic indicators for the DFS and OS of CRC patients. After adjusting for the listed key clinical prognostic factors and using a multivariate Cox regression analysis (Table 2) , the Duke stage (P = 0Á018, HR = 2Á196, 95% CI = 1Á143-4Á220 and P = 0Á019, HR = 2Á197, 95% CI = 1Á139-4Á237), histological grade (P = 0Á004, HR = 0Á465, 95% CI = 0Á275-0Á783 and P = 0Á000, HR = 0Á341, 95% CI = 0Á199-0Á585), metastasis (P = 0Á000, HR = 7Á283, 95% CI = 3Á500-15Á158 and P = 0Á000, HR = 5Á455, 95% CI = 2Á622-11Á350) and CD33 scores (P = 0Á001, HR = 4Á245, 95% CI = 1Á830-9Á850 and P = 0Á000, HR = 6Á582, 95% CI = 2Á481-17Á460) were independent predictors for the DFS and OS of CRC patients. Taken together, these data indicated that tumour-infiltrating CD33 + MDSCs had independent prognostic value in CRC patients, but YAP1 and PTEN did not.
CRC-mediated functional MDSC induction is associated with YAP1 and PTEN expression
We continued to detect the expression of YAP1 and PTEN in CRC cell lines. We found that YAP1 and PTEN were highly expressed in SW620 cells compared with LS174T, LOVO and SW480 cells (Fig. 3a) . Therefore, as in our previous study, we analysed the induction of MDSCs mediated by co-culture with colorectal cells and observed that an increased percentage of CD33 + CD11b + HLA-DR À MDSCs was induced by SW620, LS174T or SW480 cells (Fig. 3b) . Moreover, the suppression of SW620-induced and LS174T-induced MDSCs on the proliferation of T cells, including CD4 + and CD8 + T cells, was stronger than that of control CD33 + cells in medium alone (Fig. 3c ).
YAP1 and PTEN modulate CRC-derived MDSC induction through regulating GM-CSF secretion
YAP1 and PTEN expression was blocked by siRNA targeting of YAP1 or PTEN, or the YAP1 inhibitor verteporfin in CRC-derived cells in this study. We found that the blockade of YAP1 decreased the expression of both YAP1 and PTEN, whereas the blockade of PTEN decreased the Fig. S1A ). These observations indicate that YAP1 promotes CRC-mediated MDSC induction by suppressing PTEN expression in CRC-derived cells.
To further investigate the molecular mechanisms of YAP1-and PTEN-mediated CRC-induced MDSC expansion, we determined that the secretion of GM-CSF was decreased in SW620-siYAP1 and LS174T-siYAP1 cells but increased in SW620-siPTEN and LS174T-siPTEN cells or SW620-siYAP1, SW620 + verteporfin, LS174T-siYAP1 or LS74T+verteporfin cells once PTEN was knocked down (Fig. 5a , and see Supplementary material, Fig. S1B) . Importantly, the expression of molecules related to MDSC differentiation, including P-AKT, P-p65 and COX-2, was increased in SW620-siPTEN and LS174T-siP-TEN cells but decreased in SW620-siYAP1 and LS174T-siYAP1 cells or verteporfin-treated cells (Fig. 5b , and see Supplementary material, Fig. S1C ). These observations indicated that the activation of YAP1 could suppress PTEN expression in CRC, which could potentially affect CRC-derived MDSC expansion by regulating the activation of the P-AKT, P-p65 and COX-2 pathways to produce the cytokine GM-CSF (Fig. 5c) .
Discussion
In our previous study, we found that the MDSC population was expanded in the peripheral blood and tumour tissues of CRC patients; in turn, these MDSCs inhibited T-cell proliferation and promoted CRC cell growth in vitro.
14 In the present study, we further demonstrated that the density of CD33 + MDSCs was correlated with the expression of YAP1 and PTEN in the CRC microenvironment; furthermore, all these factors were predictors for the DFS and OS of CRC patients. Importantly, the CD33 + MDSC density is an independent factor of poorer CRC patient survival. The associations between ectopic YAP1 and PTEN expression and MDSC induction were further determined using an in vitro analysis, which revealed an association with the activation of the MDSCrelated molecules COX-2, P-AKT and P-p65 by the up-regulation of YAP1 and the subsequently induced down-regulation of PTEN, resulting in the secretion of GM-CSF from CRC-derived cells. Overall, these findings suggest that aside from their direct oncogenic role in CRC, YAP1 and PTEN are involved in tumour development through promoting pro-tumorigenic MDSC expansion.
The MDSC expansion and the resulting suppression of anti-tumour immunity is a general phenomenon in some cancer types, such as CRC. 14, 18 However, the phenotype and induction of MDSCs varies extensively among different cancer types, and the molecular mechanism of MDSC induction has remained largely unclear until now. Here, we first demonstrated three associations among CD33 + MDSC, YAP1 and PTEN levels in clinical specimens from CRC patients: the number of
CD33
+ MDSCs was positively associated with the level of YAP1 (P = 0Á005) but negatively associated with the level of PTEN (P = 0Á040), and the level of YAP1 was negatively correlated with that of PTEN (P = 0Á042) in the CRC microenvironment. We further demonstrated a strong, positive correlation between tumour-infiltrating CD33 + MDSC and YAP1 levels and advanced clinicopathological features, including the Duke stage, histological grade and metastatic status (P < 0Á05), all of which are signatures of a poor clinical outcome. However, a negative correlation was found between the PTEN level and advanced clinicopathological features, including the Duke stage and histological grade (P < 0Á05). Hence, CD33 + MDSCs and YAP1 were predictors for reduced DFS and OS (P < 0Á05), whereas PTEN was a predictor for favourable DFS and OS (P < 0Á05). However, after adjusting the Cox model to include histological grade, metastatic status and CD33 + MDSC, YAP1 and PTEN levels, only the CD33 + MDSC level was an independent predictor in CRC patients. These data indicate that tumour YAP1 and PTEN expression might mediate CRC tumorigenesis in association with the induction of MDSCs in the tumour microenvironment. To date, the contributions of MDSCs, YAP1 and PTEN to tumour prognosis in CRC have not been verified; hence, this report is the first to describe the correlations among 
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+LS174T-Si-CON +LS174T-Si-PTEN +LS174T+Si-YAP1 +LS174T-Si-PTEN+YAP1 MDSCs, YAP1 and PTEN and their prognostic values in CRC patients. YAP1 is activated in CRC-derived cells and CRC and is correlated with CRC cell growth and proliferation, 19 and low PTEN expression has been identified in CRC tissues and CRC-derived cell lines and is also associated with tumour progression. 8, 9 The down-regulation of PTEN in CRC tissues is reported to be induced by PTEN gene mutation or deletion. 20 However, a recent study demonstrated that YAP1 down-regulates PTEN expression by inducing microRNA 29 (miR29) to inhibit PTEN translation. 21 Here, we found that the levels of YAP1 and PTEN expression in CRC-derived cells reflected the induction of functional CRC-mediated MDSCs in vitro. Furthermore, our data showed that YAP1 and PTEN are involved in CRCderived MDSC induction, and YAP1 promotes CRCderived MDSC induction by suppressing PTEN expression.
In melanoma patients, the loss of PTEN in tumour cells is linked to resistance to T-cell-based immunotherapies and inferior outcomes of anti-PD-1 immunotherapy, which are associated with immunosuppression in the tumour microenvironment. [22] [23] [24] In a murine model, miRs, including miR-155, miR-21 and miR-494, can inhibit MDSC expansion and activity by targeting PTEN. 15, 25, 26 Importantly, recent studies have revealed that YAP1 is activated in prostate cancer and drives MDSC recruitment through heterotypic CXCL5-CXCR2 signalling. 15 In addition, YAP1 suppresses PTEN expression by inducing miR-29 to inhibit PTEN translation, which is associated with the regulation of cell growth and proliferation. 27 In the present study, we first identified that YAP1 can modulate tumour-associated MDSC induction through suppressing PTEN expression to activate P-AKT, P-p65 and COX-2 and subsequently induce the secretion of GM-CSF, which is associated with the expansion of MDSCs in CRC (Fig. 5c) . In addition to their direct contributions to oncogenesis in CRC, ectopic YAP1 and PTEN expression may lead to immunosuppression by inducing CRC-derived MDSC expansion. These findings indicate, for the first time, a novel molecular mechanism for MDSC expansion in CRC and may guide the future development of therapeutic strategies for CRC patients.
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